Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:REPL 21 October 2025

Replimune Stock Rockets 100% on FDA Nod – Analysts Eye Upside

Replimune Stock Rockets 100% on FDA Nod – Analysts Eye Upside

Replimune shares jumped 99% to $8.94 on Oct. 20, 2025, after the FDA accepted its resubmitted BLA for lead cancer therapy RP1 plus nivolumab, setting a PDUFA decision date for April 10, 2026. New trial data showed a 44% response rate in acral melanoma. The stock’s rebound follows a 73% plunge in July after an FDA rejection. Market cap stands near $698 million.
21 October 2025
·

Stock Market Today

  • Entergy (ETR) Appears Deeply Undervalued Following Recent Price Dip
    March 20, 2026, 6:55 PM EDT. Entergy (ETR) shares fell 5.4% over the past week and 2.4% over 30 days, despite a 22.4% gain in the past year. The U.S. utility faces scrutiny on regulation and capital spending amid rising interest rates, influencing investor sentiment. A Discounted Cash Flow (DCF) analysis projects an intrinsic value of $489.51 versus the current price near $99.90, suggesting the stock is undervalued by approximately 79.6%. The model considers future free cash flows turning positive by 2030 after several years of losses. Entergy holds a moderate valuation score of 3 out of 6, signaling some uncertainty. Investors should weigh the DCF findings against market risks and regulatory factors when assessing Entergy's use in portfolios.
Go toTop